Sunday, January 19, 2020 12:50:01 PM
Medistem started in 2008 and was sold about five years later. CMTH has been around for several years. They are working on the end game IMO, not a traders desires. What has led us to this point has many reasons.
If all the 9 doctors that signed in 2018 came on line in the fall when we were moving, things would have been fine. Having 3 drop out was not good, but the long delay of switching to CaverStem 2.0 was the big problem IMO. That delayed the remaining doctors from getting up and running until spring 2019. By then the damage was done. The price dropped to .01 and caused more notes to be issued.
Waiting to add the first 100 CaverStem 2.0 patients to the clinical paper was brilliant, but damaging. It caused many of the next round of doctors to hold off and not sign up. Everything flatlined in 2019 waiting on the extended paper. To keep the doors open there were occasional notes for roughly $300,000 to keep the company running.
This is the one thing I agree with Hornet on. It is toxic financing. They cannot get a traditional loan. The notes spiral out of control when they convert lower and lower. I am sure you know that for each tic the PPS dropped, the more shares were needed for each note and on and on. Shorty isn’t stupid, he jumps in like a shark to chum and here we sit. The company didn’t dump shares, the notes did.
No obvious fraudulent intentions of the officer(s), it was the delays and and lack of revs. There is no scam, no fraud, no scheme. It’s a work in progress on their time scale, not ours.
The clinical trial is out now, and it’s clear CaverStem is safe and very effective. There is evidence all around the world that it works. Dig a little and you will find it.
What’s different now? With the clinical trial is out, doctors will be signing up now, FemCelz is ready and StemSpine is ready. In fact, I bet we will all be amazed on what we discover about StemSpine.
The situation is very positive right now. The only question is..... is it too late to save the patient?
I don’t think so and I still have my shares to prove it. I am no fan of a RS, especially in the OTC, but with or without it, CELZ can thrive.
We will know in the next few months.
Recent CELZ News
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2023 08:05:12 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
- Creative Medical Technology Announces $2 Million Share Repurchase Program • PR Newswire (US) • 06/12/2023 12:01:00 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 06/12/2023 12:00:00 PM
- Creative Medical Technology Holdings Announces Reverse Stock Split • PR Newswire (US) • 06/09/2023 04:30:00 PM
- Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform • PR Newswire (US) • 05/31/2023 12:00:00 PM
- Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development • PR Newswire (US) • 05/22/2023 12:30:00 PM
- Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line • PR Newswire (US) • 05/18/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM